Experts say Afrezza's tepid launch may have more to do with value proposition than product positioning.
Endo agrees to buy Par Pharmaceuticals for $8 billion; AstraZeneca deepens commitment to biologics; FDA cautions that certain diabetes drugs could lead to serious condition
Hernandez is known for his ability to bring together patients and pharma. He joined Livongo Health to aid the firm's user experience.
FDA advisory panel recommends Amgen's T-Vec; Teva again makes the case for a merger with Mylan; the FDA approves injection to treat double chins
Merck said Januvia is not linked to higher heart-failure risk; Biogen plans to spend $2.5 billion on Alzheimer's disease; Mylan rejected Teva's bid
First-quarter sales fell 1% but the drugmaker expects 2015 to be a growth year.
Despite an FDA committee voting that AstraZeneca's diabetes medication carries an acceptable heart risk, analysts say a Merck study will determine the DPP-IV category's fate.
An FDA panel said heart risks should be part of Onglyza's label; the OIG will examine generic price increases; Abbott said its OTC glucose meter will save patients money
Sanofi won't discount new insulin; Takeda appoints new US business head; insurers push back on expensive preventative genetic tests
AstraZeneca diabetes drug may have increased mortality rate; Pfizer accused of knowing about birth defect risks from Zoloft; Eisai to cut 25% of its US workforce
The panel will focus on heart failure hospitalization rates associated with the diabetes medication.
Takeda proposes $2.2-billion settlement to resolve Actos suits; Public Citizen says diabetes drugs are unlawfully promoted; PAIN study says 20% to 30% of opioid drugs are misused
Novo announces it will resubmit Tresiba to the FDA; WHO urges Europe to share cost-effectiveness data; J&J and Google partner to develop robotic surgery system
A Florida Congressman introduced a bill that would expand patent protections; Novo Nordisk expects to increase diabetes medication prices; AbbVie expanded its Alzheimer's research
Oncology and diabetes medications are expected to be major areas of growth.
The diabetes device manufacturer will soon work with Glooko's platform.
The SEC said some company drug prices can be made public, 23andMe launched an R&D division, and Public Citizen is asking the FDA to withdraw a proposal it says will undermine drug safety information.
The partners will focus on developing treatments for metabolic disorders.
NICE greenlights Harvoni for Britain's national formulary, Pacira received a CRL instead of an expanded indication and Novo's latest diabetes outreach focuses on patients instead of drug brands.
Potential patients are expected to be newly diagnosed diabetes patients as opposed to Lantus switchers.
The EU will have access to the new medication in May.
The drugmaker wants to put the drug through additional liver-impact tests.
An NIH study shows possible limit to Lucentis's appeal.
A Merck survey that indicated distaste for British Columbia's decision to boot Januvia from the formulary has stirred up debate over bias.
Achillion's experimental HCV drug cleared the virus in six weeks when combined with Gilead's Sovaldi; Sanofi will replace a third of its sales managers; GSK shutters Montana vaccine R&D.
The reason: higher prices and more services.
The drugmaker says its Trulicity focus now includes primary care doctors in addition to specialists, and that foreign exchange will take a bite out of 2015 performance.
Doximity professional network now includes financial data; Pfizer settles class-action lawsuit; researchers hope to use temporary tattoos to identify glucose levels.
Sandoz received FDA biosimilar nod; new technique yields 25 antibiotics; Novartis sends two COPD drugs for FDA review.
The company is set to introduce its newest brand, Saxenda, into the crowded prescription obesity market as a higher-dose form of liraglutide than diabetes shot Victoza.
Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.